Use of Serum Micro RNA s as Biomarker for Hepatobiliary Diseases in Dogs
Autor: | Dirksen, K, Verzijl, T, Grinwis, G C, Favier, R P, Penning, L C, Burgener, I A, van der Laan, L J, Fieten, H, Spee, B, dPB CR, dCSCA RMSC-1, Regenerative Medicine, Stem Cells & Cancer, Veterinair Pathologisch Diagnostisch Cnt, Dep Pathobiologie, dCSCA AVR |
---|---|
Přispěvatelé: | dPB CR, dCSCA RMSC-1, Regenerative Medicine, Stem Cells & Cancer, Veterinair Pathologisch Diagnostisch Cnt, Dep Pathobiologie, dCSCA AVR, Surgery |
Rok vydání: | 2016 |
Předmět: |
Male
0301 basic medicine Pathology medicine.medical_specialty Adenoma 040301 veterinary sciences Standard Article Bile Duct Diseases 0403 veterinary science 03 medical and health sciences Dogs medicine Animals hepatitis Dog Diseases Retrospective Studies Hepatitis Hepatology General Veterinary business.industry Liver Diseases Hepatobiliary disease Retrospective cohort study 04 agricultural and veterinary sciences medicine.disease Standard Articles MicroRNAs neoplasia 030104 developmental biology Hepatocellular carcinoma biomarker Biomarker (medicine) Female SMALL ANIMAL Portosystemic shunt mucocele business Biomarkers |
Zdroj: | Journal of Veterinary Internal Medicine, 30(6), 1816. Wiley-Blackwell Journal of Veterinary Internal Medicine Journal of Veterinary Internal Medicine, 30(6), 1816-1823. Wiley-Blackwell |
ISSN: | 1939-1676 0891-6640 |
Popis: | Background Current biochemical indicators cannot discriminate between parenchymal, biliary, vascular, and neoplastic hepatobiliary diseases. MicroRNAs are promising new biomarkers for hepatobiliary disease in humans and dogs. Objective To measure serum concentrations of an established group of microRNAs in dogs and to investigate their concentrations in various types of hepatobiliary diseases. Animals Forty-six client-owned dogs with an established diagnosis of hepatobiliary disease and stored serum samples and eleven client-owned healthy control Labrador Retrievers. Methods Retrospective study. Medical records of dogs with parenchymal, biliary, vascular, or neoplastic hepatobiliary diseases and control dogs were reviewed. Concentrations of miR-21, miR-122, miR-126, miR-148a, miR-200c, and miR-222 were quantified in serum by real-time polymerase chain reaction. Results No different microRNA concentrations were found in the adenoma and congenital portosystemic shunt groups. In all other diseases, miR-122 concentrations were elevated with the highest concentration in the mucocele group (267-fold, CI: 40–1,768, P < .001). In dogs with biliary diseases, miR-21 and miR-222 were only increased in dogs with mucoceles (26-fold, CI: 5–141, P = .005 and 13-fold, CI: 2–70, P = .025, respectively). Uniquely increased microRNAs were found in the hepatocellular carcinoma group (miR-200c, 35-fold increase, CI: 3–382, P = .035) and the chronic hepatitis group (miR-126, 22-fold increase, CI: 5–91, P = .002). Conclusions and Clinical Importance A microRNA panel consisting of miR-21, miR-122, miR-126, miR-200c, and miR-222 can distinguish between parenchymal, biliary, and neoplastic hepatobiliary diseases. Serum microRNA profiling is a promising new tool that might be a valuable addition to conventional diagnostics to help diagnose various hepatobiliary diseases in dogs. |
Databáze: | OpenAIRE |
Externí odkaz: |